StockTipsArenaBeta

BUY Aurobindo Pharma — Rajesh Bhosale, Angel One

BUYAurobindo Pharma

byRajesh Bhosale, Angel OneHorizon: NA (inferred Swing (≤2wk))29 Sept 2026via ET Now (Live)

Entry₹1,704.2Inferred
Target₹1,760
Total upside +3.27%
Stop loss₹1,670-2.01% risk
CMP₹1,708.7Just now
Active+0.26%+3.00%upside left 14d left
Follow Rajesh Bhosale for new calls(32% target hit, 25 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 1 other Swing call on AUROPHARMASee 106 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 29 Sept, 2:36 pm IST
12 supporting1 neutral1 opposing
Supports the BUY call (12)

MACD above its signal line — bullish momentum

Technicals · macd·29 Sept · today

Aurobindo Pharma stock in focus after subsidiary Unit-IV receives VAI status from US FDA

NewsGoogle News·23 Sept · 5d ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·24 Sept · 5d ago

Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong

NewsGoogle News·22 Sept · 6d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·21 Sept · 1w ago

Neutral / worth noting (1)

Aurobindo Pharma AGM results: ₹4 dividend confirmed, K. Nithyananda Reddy reappointed amid dissent

NewsGoogle News·20 Sept · 1w ago

(opens in new tab)
Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.